To estimate fatal and nonfatal opioid overdose events in pregnant and postpartum women in Massachusetts, comparing rates in individuals receiving and not receiving pharmacotherapy for opioid use disorder (OUD).
RESULTS: Among 177,876 unique deliveries, 4,154 (2.3%) were to women with evidence of OUD in the year before delivery, who experienced 242 total opioidrelated overdose events (231 nonfatal, 11 fatal) in the year before or after delivery. The overall overdose rate was 8.0 per 100,000 person-days. Overdoses were lowest in the third trimester (3.3/100,000 person-days in the third trimester) and then increased in the postpartum period with the highest overdose rate 7-12 months after delivery (12. 3/100,000 person-days). Overall, 64.3% of women with evidence of OUD in the year before delivery received any pharmacotherapy in the year before delivery. Women receiving pharmacotherapy had reduced overdose rates in the early postpartum period.
CONCLUSION: Pregnant women in Massachusetts have
high rates of OUD. The year after delivery is a vulnerable period for women with OUD. Additional longitudinal supports and interventions tailored to women in the first year postpartum are needed to prevent and reduce overdose events. O pioid-related overdose deaths have more than quadrupled over the past 15 years, representing a public health emergency. [1] [2] [3] The rates of heroin use and prescription opioid-related overdose deaths are rising faster in women than in men, particularly women of reproductive age. [4] [5] [6] Multiple states have identified opioid-related overdoses as a major contributor to pregnancy-associated deaths. Among all preg-nancy associated deaths, 11-20% were the result of opioid overdose. [7] [8] [9] Recent estimates of opioid use disorder (OUD) range from 0.4 to 0.8% during pregnancy to 2% among women of reproductive age. 10, 11 Pregnancy is often seen as a motivating time for women to reduce substance use and begin substance use treatment. 12, 13 For pregnant women with OUD, the standard of care is behavioral therapy and pharmacotherapy with methadone or buprenorphine, which improves obstetric, neonatal, and substance use outcomes. [14] [15] [16] [17] Although many pregnant women with OUD initiate pharmacotherapy, disengagement from pharmacotherapy occurs at high rates, increasing the risk of relapse. 18, 19 Little is known about the timing of opioid-related overdoses and the relationship of pharmacotherapy to relapse during the prenatal and postpartum periods.
The purpose of this study is to explore the effect of overdose events in pregnant and postpartum women in Massachusetts using a linked statewide population-level data set. Our study aims were to 1) investigate trends in overdose events in women with OUD in the year before and after delivery and 2) compare overdose rates by receipt of pharmacotherapy. We hypothesized that the rate of overdose events decreased as pregnancy progressed but increased after delivery and overdose rates were lower in women receiving pharmacotherapy.
MATERIALS AND METHODS
We conducted a population-based retrospective cohort study using a statewide linked database created in response to a mandate from the Massachusetts legislature and overseen by the Massachusetts Department of Public Health. 20 Chapter 55 of the Acts of 2015 mandated that the Massachusetts Department of Public Health analyze data from several Massachusetts government agencies to identify and report on fatal and nonfatal opioid overdose trends. 20 Linkage across data sets at the individual level allowed for a deeper understanding of the circumstances that influence opioid overdoses. The following data sources for calendar years 2011-2015 were linked at the individual level to allow for a deeper understanding of the circumstances that influence overdose: the Massachusetts All Payer Claims Database, inpatient hospitalization, emergency department visits, and outpatient observations from the Center for Health Information and Analysis discharge records, vital records birth and death certificates, Bureau of Substance Addiction Services substance use disorder treatment data, the Massachusetts Prescription Drug Monitoring Program, and Massachusetts Ambulance Trip Record Information System, among others. A full description of the data sets linked, data structure, and linkage rates across data sets has been described previously by the Massachusetts Department of Public Health. 21, 22 For the All Payer Claims Database, the core data set for which all other data were linked to, medical claims from insurers are normalized to ensure completeness and validity and enable accurate cross-payer and cross-provider research and analyses. 23 In general, for each independent data set linked to the Chapter 55 data set, data collection, maintenance, and internal validation is performed by the Massachusetts public health agency responsible for that database.
We included all Massachusetts female residents who delivered a liveborn neonate (with a gestational age of 20 weeks or greater), identified through linkage with a birth certificate. Birth certificate linkage rates for our study period were 91.7%. Our study cohort was limited to deliveries that occurred between January 1, 2012, and September 30, 2014, to allow for a full year of available data before and after each delivery. The study population includes both singleton and multiple births as well as multiple deliveries to the same woman in the study period. Appendix 1, available online at http://links.lww.com/AOG/B116, shows schematically how the study population was defined.
To focus on women who would most benefit from pharmacotherapy during pregnancy and the postpartum period, we further restricted the cohort to individuals with evidence of OUD in the year before delivery. Evidence of OUD was defined as the presence of any of the following criteria in linked records: 1) International Classification of Diseases, 9th Revision, Clinical Modification and 10th Revision, Clinical Modification codes related to OUD in hospital discharge or claims records 24 ; 2) an opioid overdose event, as further defined subsequently; 3) enrollment in a state-funded treatment program for an "opioid problem"; 4) claims for methadone maintenance treatment (including only Healthcare Common Procedure Coding System code H0020 [methadone administration by a licensed program] to exclude claims of methadone prescribed for pain); 5) receipt of methadone from a state-funded treatment program; 6) filled prescription for buprenorphine or combined buprenorphine and naloxone; or 7) diagnosis of neonatal abstinence syndrome. Diagnoses of neonatal abstinence syndrome were identified through linked infant claims records. For mothers identified solely by a diagnosis of neonatal abstinence syndrome, children born at 34 weeks of gestation or less were excluded to prevent misclassification of iatrogenic cases of neonatal abstinence syndrome.
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Appendix 2, available online at http://links.lww.com/ AOG/B116, specifies the International Classification of Diseases codes used for case identification, and Appendix 3, available online at http://links.lww. com/AOG/B116, shows the proportion of deliveries with evidence of OUD identified from each data source and proportion of deliveries identified uniquely by only a single data source. Our primary outcome of interest was fatal or nonfatal opioid-related overdose events. Opioidrelated overdose events were defined as having any of the following: 1) a death certificate indicating opioid overdose as the cause of death; 2) an admission to an inpatient unit, observation unit, or an emergency department encounter with an indication of opioid overdose based on International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes for opioid poisoning (Appendix 2, http:// links.lww.com/AOG/B116); or 3) an ambulance incident with an indication of opioid overdose based on an algorithm created and refined by the Massachusetts Department of Public Health in collaboration with the Centers for Disease Control and Prevention (data available from January 1, 2013, to December 31, 2015) ; to assess for validity across multiple data sets, the number of overdose events reported after a confirmed death was assessed and found to be zero (Appendix 4, available online at http://links.lww. com/AOG/B116). Additionally, ambulance and hospital encounters recorded on the same calendar day were assumed to describe a single overdose event (Appendix 4, http://links.lww.com/AOG/B116). Because our identification of pregnancy relied on the delivery of a liveborn neonate, women who may have had a fatal overdose while pregnant were not able to be identified.
We compared the characteristics of our cohort with evidence of overdose events, with those who had evidence of OUD in the year before delivery but without overdose, and all other women who delivered a liveborn neonate using descriptive statistics and x 2 tests. Maternal age in the year of delivery, race and ethnicity, marital status, employment status, highest educational level, and the adequacy of prenatal care utilization index 25 were extracted from birth certificate data. Evidence of homelessness was defined as homelessness at any time during the study period from 2011 to 2015, identified from predictive modeling in the overall linked data set. 24 Finally, evidence of anxiety and depression was recorded from claims data and was defined as any claim during the entire study period from 2011 to 2015. All analyses were performed in SAS Enterprise.
The years before and postdelivery were divided into eight time periods of interest using date of delivery and gestational age recorded on the birth certificate. The year before delivery was divided into four periods: 1) preconception, representing the time from 1 year before the due date to conception; 2) first trimester; 3) second trimester; and 4) third trimester, which varied in length based on gestational age (Appendix 5, available online at http://links.lww. com/AOG/B116). The year after delivery was equally divided into four 3-month intervals: 5) 0-3 months; 6) 4-6 months; 7) 7-9 months; and 8) 10-12 months. The number of days each woman spent in each time period was totaled to calculate the number of persondays. For each time period, the total number of overdose events and person-days under observation were calculated for the cohort and used to estimate a set of overall overdose rates. Women were not censored when experiencing a nonfatal overdose event, but were censored at the time of death. Given overdose was a rare event, 95% CIs were computed using the Poisson distribution.
Monthly receipt of pharmacotherapy was determined based on evidence of 1) a claim for methadone maintenance (as described previously), 2) enrollment in a state-funded opioid treatment program receiving methadone, or 3) a filled prescription containing buprenorphine. Because use of naltrexone is not standard practice during pregnancy, this medication was not included. Overdose events were then classified into two groups: occurring in a month when the woman had any evidence of receipt of pharmacotherapy ("overdose events on pharmacotherapy") or occurring in a month when a woman had no evidence of receipt of pharmacotherapy ("overdose events without pharmacotherapy"). To determine the total number of person-days that contributed to the denominator for the rate in each group, we had to estimate the number of days on which an individual had received pharmacotherapy from the treatment data that were available on a monthly basis. As a result of privacy limitations on the data set, we could not identify the specific day in a calendar month that the delivery took place. To account for this limitation, in the month of delivery, individuals were assigned an equal number of person-days to the period just before and after pregnancy. For example, if a woman had received treatment during the month of delivery, she would contribute 15 person-days to the denominator of the third trimester "on pharmacotherapy" period and 15 person-days to the denominator of the 0-3 months postpartum "on pharmacotherapy" period." From here, monthly treatment data were then Copyright Ó by American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc.
mapped onto the eight time periods described previously. Appendix 5 (http://links.lww.com/AOG/ B116) shows the amount of time each delivery contributed to each time period based on gestational age. Next, two sensitivity analyses were performed. First, to examine the effect of including multiple deliveries for the same woman, we compared overdose rates for the entire cohort with rates including only a woman's first delivery during the study period. Second, we evaluated the number of women who had an overdose event in the year after delivery but had no evidence of OUD in the year before delivery. We then compared the rates when including all women with evidence of OUD during the year before or postdelivery with the rates from the original cohort.
This work was mandated by law and conducted by a public health authority. The Massachusetts Department of Public Health was not engaged in human subjects research, and as a result, it was determined that no institutional review board was required. The Boston University institutional review board additionally deemed this study nonhuman subjects research.
RESULTS
A total of 169,206 Massachusetts female residents who delivered a liveborn neonate were identified during the study period, experiencing 177,876 unique deliveries, representing 183,466 unique births (Fig. 1 ). There were 6,861 (3.9%) deliveries to women with evidence of OUD documented any time from 2011 to 2015 and 5,016 (2.8%) deliveries to women with evidence of OUD in the year before or postdelivery. In our cohort, there were 4,154 (2.3%) deliveries to women with evidence of OUD in the year before delivery. Overall, there was a total of 242 overdose events (231 nonfatal and 11 fatal) occurring among 184 deliveries in our cohort. In 25% of deliveries, a woman experienced more than a single overdose event within the year before or after delivery with the number of overdose events experienced per individual ranging from one to four.
The characteristics of the sample population are described in Table 1 . Compared with women with evidence of OUD who had no overdose events and all women who delivered a liveborn neonate, women with an overdose event were more likely to be younger, single, unemployed, lacking a high school degree, receiving public insurance, and receiving inadequate prenatal care. Women with an overdose event had significantly higher co-occurring homelessness and psychiatric conditions. Seventy-nine percent of women with an overdose event had some evidence of homelessness compared with 34% of women with OUD but no overdose and 2% of women who delivered a liveborn neonate without OUD (P,.001). Women with an overdose event were significantly more likely to have evidence of anxiety (82% with overdose vs 60% with OUD but no overdose vs 18% of deliveries without OUD [P,.001]) and depression (85% with overdose vs 61% with OUD but no overdose vs 19% of deliveries without OUD [P,.001]). Overall, 64.3% of deliveries to women with evidence of OUD received any pharmacotherapy in the year before delivery.
The overall rate of opioid-related overdose events in the cohort was 8.0 per 100,000 person-days. Overdose events decreased as women progressed throughout pregnancy and were lowest in the third trimester at 3.3 per 100,000 person-days (95% CI 1.6-6.1/ 100,000 person-days) and then increased in the postpartum period ( Table 2 ). The highest risk of overdose occurred 7-12 months after delivery, when the rate was 12.3 per 100,000 person-days (95% CI 9.9-15.0/ 100,000 person-days). When comparing opioid overdose rates by receipt of pharmacotherapy, rates on treatment are lower than rates off treatment in every time period except for the third trimester, when the number of events was low in both groups, but only reached statistical significance in the 4-6 months postdelivery (1.3/100,000 person-days on pharmacotherapy [95% CI 0. .74] vs 10.7/100,000 person-days Unauthorized reproduction of this article is prohibited. Table 2 ; Fig. 2 ). At 7-12 months postpartum, the opioid overdose rates increased for both women receiving pharmacotherapy and those not receiving treatment (Fig. 2) . The number of overdose events and number of person-days in each time period are shown in Appendix 6, available online at http://links. lww.com/AOG/B116. We identified 6.6% of the deliveries in the cohort as second or third deliveries to the same woman. Restricting our cohort to just a single delivery per woman did not significantly change the opioid overdose rates (data not shown). Finally, there were 78 women, each with a single delivery, who had 93 opioid-related overdose events in the year after delivery, but had no evidence of OUD in the year before delivery. Deliveries among these women (no OUD prenatally, overdose postnatally) were significantly more likely to occur in women who were younger than 25 years, were nonwhite, had paid employment, received adequate prenatal care, had private insurance, had evidence of homelessness, and did not have a diagnosis of anxiety or depression compared with women with an overdose who had evidence of OUD in the year before pregnancy (P value for all analyses ,.05).
DISCUSSION
Using a unique population-based linked data set to identify women with OUD, we determined the timing and rates of fatal and nonfatal overdose events among women who delivered a liveborn neonate in Massachusetts. Overdose events were lowest in the third trimester but increased after delivery with the highest rates 7-12 months postpartum. Overall, overdose rates among women receiving pharmacotherapy in the month of overdose were statistically significantly lower compared with those not receiving pharmacotherapy. Additionally, pregnant women in Massachusetts with OUD had significantly higher rates of homelessness and psychiatric conditions compared with all other pregnant women in Massachusetts.
Our study identified the first year postpartum as a period when mothers are at higher risk of overdose events. We hypothesize several explanations. First, compared with the prenatal period when resources are prioritized for pregnant women with OUD, the postpartum period can be difficult because fewer special services continue after delivery. 26, 27 Second, the shame and stigma mothers experience watching their neonate's symptoms of withdrawal from in utero opioid exposure can make the immediate postpartum period particularly challenging. 28, 29 Third, postpartum hormonal changes can make it difficult to determine the optimum pharmacotherapy dose for maintaining recovery. 30 Fourth, the high rates of cooccurring depression, anxiety, and homelessness may put women at higher risk of postpartum depression, which has been shown to affect relapse. 31 The second 6 months after delivery were a particularly vulnerable period. Discontinuing pharmacotherapy in the postpartum period may play a role in the higher overdose rates, because retention is associated with significant reductions in overdose mortality in all persons with OUD. 32 Few studies have previously reported on postpartum pharmacotherapy discontinuation, yet in a single-site cohort of methadone-maintained mothers with OUD, Wilder and colleagues 18 found a 56% discontinuation rate by 6 months postpartum. In our cohort, relapse may have occurred significantly earlier than an overdose event that requires medical attention, but the presence of more potent synthetic opioids such as illicitly manufactured fentanyl in the heroin supply increases the risk of overdose during a first relapse. 33 Finally, we found that 2% of women had evidence of OUD in the year before delivery, higher than the previously published national representative samples of OUD in pregnancy of 0.4-0.8%, although definitions of OUD differ across the studies. 10, 11 Our data set allowed for a broader and more contemporary examination of OUD throughout pregnancy, relying on multiple different data sources and touchpoints with the health care system before a woman's delivery for a more inclusive understanding of the burden of OUD in pregnant women in Massachusetts, a state significantly affected by the opioid epidemic. 24 Our study is subject to several limitations. First, we identified our cohort of women based on the linkage with a newborn's birth certificate and were unable to identify pregnant women who experienced a fatal overdose during pregnancy, died from another cause, or did not deliver a liveborn neonate. Therefore, our study may underestimate the burden in the prenatal period. Second, because treatment data were only available on a monthly basis, we could not determine whether an individual was actively receiving treatment when overdose occurred. It is possible that some people discontinued treatment before the overdose event or started after, thus resulting in a misclassification as receiving pharmacotherapy, biasing observed overdose event rates higher while on treatment. Third, although we estimated the number of person-days just before and after delivery, we do not expect this estimation biased our findings toward either the treated or untreated group. Fourth, these analyses did not adjust for potential confounding factors that may be associated with both receipt of treatment and overdose. Fifth, ambulance trip data were not available until 2013, potentially affecting our ability to identify some overdose events not ending in transport to an emergency department. Finally, we relied on the use of administrative and 
